In a press release, MindChild Medical Inc. announced a sponsored research agreement with The University of Oxford. The research program will explore the development of new signal processing systems for monitoring fetal and maternal heart rates with non-invasive systems. Dr. Gari Clifford, a faculty member at the University of Oxford, will manage the sponsored research agreement. His roles at the school include lecturing and managing the Intelligent Patient Monitoring Group. He also holds the position of Director of the Center for Doctoral Training in Healthcare Innovation. In his past he has also worked as Principal Research Scientist at the Laboratory for Computational Physiology.
MindChild Medical, a medical device manufacturer based in North Andover, Massachusetts, is currently developing new signal processing algorithms for its MERIDIAN non-invasive fetal heart monitoring system. The company has already received FDA clearance for its 501(k) Pre-Marketing Notification for the device. According to information released by the company, more pre-market filings will be submitted in 2013.
In a prepared statement, CEO Bill Edelman stated, “We are thrilled to have initiated this important collaboration with Oxford.” His remarks continued, “MERIDIAN is the first in a series of non-invasive fetal monitor technologies developed by MindChild that are intended to provide the healthcare community enhanced monitoring capabilities for both fetal heart rate and fetal ECG. We anticipate significant clinical interest for this innovative technology in the markets where MERIDIAN will be cleared for commercial distribution.”
Press release available at http://www.mindchild.com.